March 4, 2008 - Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced that following a meeting of the independent Data Safety Monitoring Board (DSMB), the Company received a recommendation to continue its Phase II BRAINz study with Debio 9902 SR (sustained release) for the treatment of Alzheimer’s disease (AD), without modification.The DSMB’s objective is to monitor the well being and safety of patients participating in a study and to review the safety data throughout its duration... Debiopharm's Press Release -
